Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2016 June;60(2) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2016 June;60(2):139-53

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Cite this article as

 

REVIEWS  PET AND GYNECOLOGICAL TUMORS 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2016 June;60(2):139-53

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

New radiotracers in gynecological cancer: beyond 18F-FDG

Amarnath CHALLAPALLI

Department of Clinical Oncology, Bristol Cancer Institute, Bristol, UK


PDF


Imaging plays an important role in the management of gynecological cancers. There is a clinical need for noninvasive prognostic biomarkers to provide more detailed tumor characterization at the baseline and/or early during therapy, which may potentially improve outcomes and enable a personalized treatment approach. Imaging parameters derived from PET/CT techniques are emerging as promising imaging biomarkers. This review details the current evidence and future potential of functional imaging using non-2-deoxy-2-[18F]fluoro-D-glucose (FDG) tracers in gynecological cancers.

top of page